North America Heart Pump Device Market Report by Product, Type, End Use, Countries and Company Analysis, 2025-2033

North America Heart Pump Device Market Size and Forecast 2025-2033

The North America Heart Pump Device market is set to grow from US$ 2.92 Billion in 2024 to US$ 8.1 Billion in 2033. This growth has a Compound Annual Growth Rate (CAGR) of 12% between 2025 and 2033. Contributing to this growth are the developments in medical technology, growing incidence of heart diseases, and rising geriatric population, promoting the demand for advanced heart pump solutions in the region.

North America Heart Pump Device Market Outlook

A heart pump machine is a mechanical device to aid or augment the function of the heart in patients with advanced cardiovascular disease, most notably those who have heart failure. In North America, such machines, including left ventricular assist devices (LVADs) and total artificial hearts, are reserved for their main use of enhancing blood flow and as a life-sustaining therapy for patients awaiting heart transplants or for whom surgery is not an option.

Heart pump devices help relieve symptoms associated with heart failure, such as fatigue, shortness of breath, and fluid retention, allowing patients to maintain a better quality of life. They are also utilized in critical situations, such as during high-risk surgeries or in patients recovering from heart attack.

The rise in the incidence of heart diseases across North America, underpinned by lifestyle issues and the aging population, has generated enhanced demand for such devices. Technology only advances further, and heart pump devices also become more efficient, enhancing the outcomes and broadening their usage in the clinic.

Growth Drivers in the North America Heart Pump Device Market

Rising Prevalence of Cardiovascular Diseases

The growth in the North America heart pump device market is considerably fueled by the high incidence of cardiovascular conditions like heart failure, coronary artery disease, and arrhythmia. In accordance with health statistics, there are millions of American and Canadian adults with chronic heart conditions, which in many cases lead to advanced stages necessitating advanced medical treatments like ventricular assist devices (VADs) or intra-aortic balloon pumps (IABPs). 919,032 USA individuals succumbed to cardiovascular disease in 2023. That's equivalent to 1 death in every 3. The increasing population of the elderly also adds fuel to the fire because aging is one of the main risk factors for heart failure. With lifestyle diseases like obesity, diabetes, and hypertension adding to the problem, the need for life-supporting heart pump devices is on the rise. The share of seniors (65 years and above) in the population of Canada would grow from 18.5% in 2021 to between 21.6% (slow-aging) and 29.8% (fast-aging) by 2068. The growth in the proportion of seniors would be smaller from 2030 onwards, year when all members of the baby boom would have attained the age of 65.

Technological Innovations in Heart Pump Devices

Another essential growth factor is the fast pace of innovation in heart pump technologies. Companies are emphasizing miniaturization, increased biocompatibility, and fewer complications like thrombosis or infection. Developments of fully implantable ventricular assist devices and percutaneous pumps expanded treatment options with a decrease in the patient's recovery time. Intelligent features such as remote monitoring, wireless energy transfer, and extended battery life are also improving patient quality of life. These developments are assisting doctors in treating patients better with increased confidence in using such devices. Dec 2024, Doctors now possess a new therapeutic option for pediatric patients suffering from cardiogenic shock and heart failure. Johnson & Johnson MedTech reported that the FDA has broadened the indications of the Impella 5.5 with SmartAssist and Impella CP with SmartAssist heart pumps, providing premarket approval for application in certain pediatric patients with symptomatic acute decompensated heart failure and cardiogenic shock.

Supportive Reimbursement and Healthcare Infrastructure

Good healthcare infrastructure and positive reimbursement systems in North America are critical drivers for the heart pump device market. Medicare, Medicaid, and private payers in the United States cover an extensive list of advanced cardiovascular interventions, which reduces the cost burden on patients substantially. Likewise, Canada's single-payer system for healthcare provides access to necessary care, including VADs and intra-aortic balloon therapy. Government campaigns to advance cardiac care and the availability of specialized hospitals and cardiac centers create a dynamic that supports device uptake. Moreover, ongoing education of medical professionals and access to trained surgeons increase the success rate of heart pump operations.

Challenges in the North America Heart Pump Device Market

Exorbitant Cost of Devices and Surgery

The high cost of the heart pump devices and procedures for implantation is one of the primary challenges. Ventricular assist devices, for instance, may run tens of thousands of dollars, not counting hospitalization, follow-up treatment, and possible complication management. Even though reimbursement systems are in place, not every patient can avail themselves of them, and out-of-pocket costs can be high enough to limit adoption in some segments. Hospitals and cardiac centers also see procurement and upkeep of the sophisticated devices as a big financial burden. These financial limitations frequently impede or postpone patients' access to life-saving devices, particularly among low-income groups.

Device-Related Risks and Complications

Despite advances in technology, heart pump devices have inherent risks, including blood clots, stroke, bleeding, and site infection. Long-term device reliance, such as on VADs, may also cause mechanical malfunction or replacement surgeries, both of which create health and economic burdens. Doctors are also hesitant to prescribe these devices to some patient groups due to safety issues. Additionally, patients need to be monitored for life and adhere to medical regimens strictly, which might be inconvenient for everyone. These constraints limit wider use, especially in cases of moderate heart failure where doctors might want to use alternative therapies.

North America Heart Pump Device Market

The North America heart pump device market is experiencing robust growth, underpinned by growing prevalence of cardiovascular disease, strong healthcare infrastructure, and advanced technological developments. The region has some of the world's most prominent medical device players and cardiac care facilities, which fosters innovation and uptake. The United States dominates the market, with its cutting-edge healthcare expenditure and reimbursement model, followed by Canada through its universal healthcare. Ventricular assist devices, intra-aortic balloon pumps, and fully implantable heart pumps are witnessing growing adoption in hospitals and specialty cardiac centers. Yet, high cost and complications of the devices are issues that remain. Overall, the market is poised to grow steadily as new-generation devices become part of clinical practice, enhancing patient outcomes in advanced heart failure.

North America Ventricular Assist Devices (VADs) Market

The North America ventricular assist devices (VADs) market is growing strongly because of an increasing patient population suffering from end-stage heart failure. VADs are being used more and more as a bridge to transplant, destination therapy, or bridge to recovery, providing life-critical support to patients on the wait lists for heart transplants. Fully implantable and miniaturized devices with improved durability are fueling hospital and specialty cardiac center adoption. In the United States, positive reimbursement policy has facilitated VAD use, while Canada deploys government-funded healthcare systems to ensure access. Yet, increased expense and risk of complications like bleeding or thrombosis continue to be deterrents. With continued advancements and clinical trials affirming newer designs, the North America VAD market is set for continuous growth and expanded clinical integration in the future.

North America Intra-Aortic Balloon Pumps (IABPs) Market

The intra-aortic balloon pumps (IABPs) segment occupies an important position in the North America heart pump device market because they maintain patients with acute myocardial infarction or cardiogenic shock stable. The devices are less invasive than other heart pumps and can frequently be utilized in emergency situations to enhance blood flow and minimize cardiac workload. Hospitals in the U.S. and Canada widely employ IABPs in critical care wards, especially in the care of patients who wait for advanced therapies such as ventricular assist devices or transplant. IABPs continue to be relevant despite the presence of competition from other newer percutaneous pumps and short-term mechanical circulatory support devices owing to their affordability and simplicity. The segment's steady uptake is likely to persist, especially in high-volume emergency cardiac case hospitals.

North America Implanted Heart Pump Device Market

Implanted heart pump devices, especially implantable ventricular assist devices, are gaining prominence in the management of chronic heart failure in North America. These devices offer long-term circulatory assistance, enhancing survival and quality of life in patients that are not suitable candidates for transplant or receiving donor hearts. The U.S. leads the segment with increased transplant demand and higher destination therapy adoption. Technologies like reduced device sizes, wireless charging, and enhanced biocompatibility are improving patient outcomes and driving adoption. In Canada, publicly funded healthcare makes patients accessible, but with slower adoption compared to the U.S. Despite costs and complications after implant, the implanted heart pump device market will continue to be a robust growth driver for overall regional market growth.

North America Heart Pump Device Hospitals Market

Hospitals are the focal point of the acceptance and use of heart pump devices throughout North America. Such institutions are usually the major sources of complex cardiovascular treatment, with specialists available, sophisticated operating rooms, and intensive care units. Hospitals contribute significantly to the market share of heart pump devices owing to their capability to manage complex procedures such as VAD implantation or IABP therapy. The U.S. dominates this segment, with tertiary care facilities embracing new devices backed by positive reimbursement. Canadian facilities, supported by public funding, also play an important role. Hospital investment in cardiac care facilities and tie-ups with device manufacturers also promote this market. Hospitals are the pillars of heart pump device implantation in North America, even with cost and training issues.

North America Heart Pump Device Cardiac Centers Market

Specialized cardiac facilities are becoming key stakeholders in the North American heart pump device market. Specialized in advanced cardiovascular interventions alone, these facilities tend to be referral sites for complicated cases that cannot be managed by community hospitals. Having specialized personnel and cutting-edge equipment, cardiac facilities have a significant impact on VADs and implantable heart pumps adoption. Patients enjoy highly individualized treatment, reduced recovery periods, and availability of investigational devices via clinical trials at these centers. The U.S. has a strong group of private and academic cardiac centers, whereas Canada is developing its specialized centers under public funding for healthcare. With increasing demand for complex cardiac therapies, the influence of cardiac centers on the market will continue to grow.

USA Heart Pump Device Market

The USA leads the North America heart pump device market on account of its sophisticated healthcare infrastructure, extensive healthcare expenditure, and high patient base of cardiovascular disease sufferers. A developed reimbursement system facilitates patient access to expensive interventions, making America an attractive market for ventricular assist devices, intra-aortic balloon pumps, and implantable devices. The fact that leading global medical device companies and research centers are located in this region speeds up innovation and adoption. Ongoing clinical trials and FDA clearances for second-generation devices are adding new options for treatment. Jan 2025, A group of cardiac surgeons and heart failure specialists at the University of Michigan has implanted a patient with a novel mechanical heart pump as part of a clinical trial. The trial will compare the new device with the sole current therapy for end-stage heart failure. As per the national lead investigator of the trial, also a cardiac surgeon at the U-M Health Frankel Cardiovascular Center, "This trial offers the ability to test new technology as we investigate a new potential therapy for severe heart failure-a potentially deadly condition with very few therapeutic alternatives in place."

Canada Heart Pump Device Market

Canada heart pump device market is growing consistently, facilitated by the nation's unified healthcare system, which guarantees all its population access to sophisticated cardiac therapies. The incidence of heart failure in Canada is increasing as a result of an aging population and rising risk factors of diabetes and obesity, driving the demand for devices like ventricular assist devices and intra-aortic balloon pumps. Though adoption is relatively slower compared to the U.S. because of regulation and funding mechanisms, government-supported healthcare provides access equity. Canadian hospitals and advanced cardiac facilities are progressively using implanted heart pump devices for patients waiting for transplants. Aug. 2024, Abbott received FDA approval for a label update for the HeartMate 3(TM) left ventricular assist device (LVAD). This revision excludes aspirin from regular patient treatment in an attempt to improve clinical outcomes. The shift is also recognized in Canada and the EU.

Market Segmentations

Product

• Ventricular Assist Devices (VADs)
• Intra-aortic balloon pumps (IABPs)
• Extracorporeal Membrane Oxygenation (EMCO)
• Total Artificial Hearts (TAHs)

Type

• Implanted Heart Pump Device
• Extracorporeal Heart Pump Device

End Use

• Hospitals
• Cardiac Centers
• Research Institutes

North America

• United States
• Canada

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Abbott Inc.
• Getinge AB.
• Teleflex Incorporated
• Fresenius SE & Co. KGaA
• LivaNova PLC
• CorWave SA
• JARVIK HEART, INC.
• ABIOMED